Skip to main content
Cancer Cell International logoLink to Cancer Cell International
. 2019 Jan 14;19:14. doi: 10.1186/s12935-019-0736-y

Correction to: Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients

Xin-xin Cao 1,#, Hao Cai 1,#, Yue-ying Mao 1, Qi Wu 1, Lu Zhang 1, Dao-bin Zhou 1, Jian Li 1,
PMCID: PMC6330738  PMID: 30651719

Correction to: Cancer Cell Int (2018) 18:215 10.1186/s12935-018-0716-7

Following publication of the original article [1], we have been notified that the data in Fig. 1 was wrongly presented. The correct Fig. 1 is presented below.

Fig. 1.

Fig. 1

Circos plots depicting the relative frequencies and pairwise co-occurrences of selected common genetic alterations: in all AML patients (a), separately in patients 60 years or older (b) and in patients younger than 60 years (c). The length of the arc corresponds to the frequency of the first gene mutation, and the width of the ribbon corresponds to the proportion of co-occurrence with the second gene mutation. Both the distribution of gene mutations and the pattern of mutation co-occurrences appear to be distinct between older and younger AML patients

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reference

  • 1.Cao X-x, Cai H, Mao Y-y, Wu Q, Zhang L, Zhou D-b, Jian L. Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients. Cancer Cell Int. 2018;18:215. doi: 10.1186/s12935-018-0716-7. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Cell International are provided here courtesy of BMC

RESOURCES